Reid Hoffman, the prominent venture capitalist and co-founder of LinkedIn, has made a significant decision regarding his role at Microsoft. He announced that he will not pursue re-election to Microsoft’s board during the company’s annual shareholder meeting in 2026. This strategic move allows him to dedicate his efforts towards Manas AI, a startup he co-founded with renowned oncologist Siddhartha Mukherjee. The company's goal is to harness the power of artificial intelligence in order to expedite drug discovery for aggressive cancers.
#What does Hoffman's exit mean for Microsoft and the AI landscape?
Hoffman's departure from Microsoft is noteworthy given the company’s acquisition of LinkedIn for $26.2 billion in cash, a transaction that solidified a successful partnership in technology. Since joining the Microsoft board in March 2017, Hoffman has played a critical role in witnessing Microsoft’s evolution into a leader in artificial intelligence.
Manas AI officially launched in early 2025 with a mission focused on using AI technology for drug discovery, beginning with cancers such as breast cancer, prostate cancer, and lymphoma. The startup managed to raise about $24.6 million in its initial funding round as of February 2025, contributing to total capital exceeding $50 million.
#Understanding the impact of Hoffman's previous board exits
This latest move is not his first time stepping back from a high-profile board to alleviate conflicts of interest while enhancing his focus. In March 2023, he resigned from OpenAI’s board, indicating the necessity to avoid potential conflicts with his various AI investments. This resignation occurred at a time when OpenAI was gaining immense traction, particularly as Microsoft enhanced its multi-billion-dollar collaboration with the company, creators of ChatGPT.
Overall, Hoffman’s decision to leave Microsoft signifies a strategic pivot toward a growing sector in biotechnology that seeks to merge AI with healthcare, a move that could potentially redefine drug discovery processes for oncology and beyond.